Uncertainty is the constant in today’s market. Ongoing Covid flare-ups, inflation, supply chain disruptions and now war are further intensifying an already volatile mix that’s spooking markets.
To reduce exposure to volatile market movements, investors are considering more defensive strategies. Classic defensive sectors furnish essential goods and services which consumers are unlikely to give up even in a downturn. With a steady focus on ‘healthy essentials’, RobecoSAM Sustainable Healthy Living is a thematic equity strategy that typically outperforms in down market cycles while still capturing the upside potential provided by long-term growth trends.
Amid general market misery, thematics with defensive characteristics are faring much better than other growth-focused strategies.
A healthy defense
Amid general market misery, thematics with defensive characteristics are faring much better than other growth-focused strategies. As David Kägi, portfolio manager for the RobecoSAM Sustainable Healthy Living Equities strategy, explains, “Defensive sectors generally provide stable earnings that are uncorrelated with the overall stock market. They even tend to outperform when broader markets are falling.”
Figure 1 | When market volatility rises, defensive sectors generally outperform
Over the last two decades healthcare and consumer staples stocks have provided steady above-market returns, further burnishing their reputation as safer bets in times of market turmoil. Here, high market volatility has been defined as periods when annualized market absolute volatility is 10% or more.
Source: Bloomberg, Robeco
Stable, risk-adjusted performance comes from a strong tilt towards healthcare and consumer staples sectors.
Kägi credits his strategy’s less volatile, risk-adjusted performance with its strong tilt towards healthcare and consumer staples sectors. Together these account for around two-thirds of the portfolio. “Consumer staples stocks function in a noncyclical manner, meaning they offer investors safety during recessionary climates. Food, grooming and cleaning products are typical staples that tend to generate solid profits even in slow-growth economies.” He notes consumer staples companies thrived during the pandemic’s early stages when markets overall were tanking.
Meanwhile, he describes his other defensive allocation, healthcare, as a perennial pursuit. “Demand for healthcare services is inelastic. People don’t ignore their health because of a dip in the business cycle. Healthcare stocks can expand earnings even in down markets.” He references healthcare costs in the US which are nearly 18% of GDP and says that globally, healthcare expenditures are rising, approaching USD 10 trillion annually.
He adds that more stable performance returns, many defensive stocks pay substantial dividends which have reliably increased through past market cycles. Their longevity is a strong signal of a high-quality stock backed by strong consumer trust, brand value, and good management. These same attributes also help staples navigate the changing challenges across economic cycles.
Early on in the pandemic as markets were falling, many segments of healthcare were resilient and displayed strong performance, from sophisticated biotech and pharmaceuticals churning out vaccines to makers of protective gear. Stocks of diagnostic and testing equipment benefited as well. Moreover, Kägi says pandemic pressures accelerated digitalization trends in healthcare, which has historically been slow to adopt new technologies. From vaccine development and clinical trials to telemedicine and health tracking apps, the pandemic catalyzed new avenues of growth across the healthcare supply chain. He is certain that new revenue channels will continue to grow even as the virus abates.
In consumer staples, he says demand for hygienic items like hand soap, disinfectants and anti-microbial wipes surged, as did over-the-counter retail medications and home remedies to relieve viral symptoms. Here too he is convinced that many Covid-induced attitudes and behavioral changes will stick post-pandemic, providing steady returns for the Strategy’s defensive stocks and clusters.
Spot on for long-term growth
Also underpinning the Strategy’s long-term growth potential are its focus on sustainability challenges that transcend market movements and mayhem over the longer term. “Society is confronting a series of serious health-related issues from rising healthcare costs and aging populations to the increasing prevalence of chronic illness.” He’s confident investments in preventative measures such as good nutrition and staying active will help reduce disease rates and curb healthcare’s cost creep.
Kägi says a focus on health across the entire human lifespan sets the portfolio apart from other healthcare theme strategies that tend to be treatment oriented. “We’re investing in companies that promote healthy living early on so that populations remain active and healthy well beyond retirement.” The Strategy’s convictions on shifts in consumer spending and preferences are so far spot on, as healthy changes in the UK’s consumer price index demonstrate. Donuts and men’s suits are out while lentils and sports bras are in.
Low risk, low gain, less pain
The cumulative performance since inception shows the Healthy Living Strategy has captured returns superior to those of global equity markets (MSCI World TR) over the long-term. What’s more, this cumulative outperformance has been achieved at lower volatility and risk relative to the benchmark – a hallmark of defensive strategies.
Figure 2 | Healthy returns over the long run
The portfolio maintains a low beta coefficient, a key measure of its sensitivity to market fluctuations, as well as low absolute volatility, which means returns have avoided wild swings relative to broader markets (see Table 1).
Table 1 | Solid performance with low volatility indicators
Key risk performance indicators from the RobecoSAM Sustainable Healthy Living Equities (EUR) D-share, Gross of fees. Beta shown has been annualized since inception, April 2007. All other data has been annualized over 5 years ending February 2022.
Meanwhile, solid risk-adjusted performance is also demonstrated in solid upside and downside capture ratios. The Strategy’s downside capture ratio was 0.70, meaning it has reduced the portfolio’s exposure to market losses by 30%. Meanwhile, its upside capture ratio over the same time period stands at 0.78, meaning it has captured nearly 80% of the positive returns generated when markets are rising.
For conservative investors seeking solid performance without the volatility, the Strategy presents an interesting alternative. Its tilt towards noncyclical sectors helps reduce exposure to losses in down market cycles while its unique approach to rising healthcare costs allows it to benefit from long-term sociodemographic shifts already underway. For growth-oriented investors, it provides active exposure to diagnostic and digital innovation that’s opening new frontiers in health maintenance and delivery for patients and health-conscious consumers. With these features, it’s well suited for investors concerned as much with the journey as the destination.
本文由荷宝海外投资基金管理(上海)有限公司(“荷宝上海”)编制, 本文内容仅供参考, 并不构成荷宝上海对任何人的购买或出售任何产品的建议、专业意见、要约、招揽或邀请。本文不应被视为对购买或出售任何投资产品的推荐或采用任何投资策略的建议。本文中的任何内容不得被视为有关法律、税务或投资方面的咨询, 也不表示任何投资或策略适合您的个人情况, 或以其他方式构成对您个人的推荐。 本文中所包含的信息和/或分析系根据荷宝上海所认为的可信渠道而获得的信息准备而成。荷宝上海不就其准确性、正确性、实用性或完整性作出任何陈述, 也不对因使用本文中的信息和/或分析而造成的损失承担任何责任。荷宝上海或其他任何关联机构及其董事、高级管理人员、员工均不对任何人因其依据本文所含信息而造成的任何直接或间接的损失或损害或任何其他后果承担责任或义务。 本文包含一些有关于未来业务、目标、管理纪律或其他方面的前瞻性陈述与预测, 这些陈述含有假设、风险和不确定性, 且是建立在截止到本文编写之日已有的信息之上。基于此, 我们不能保证这些前瞻性情况都会发生, 实际情况可能会与本文中的陈述具有一定的差别。我们不能保证本文中的统计信息在任何特定条件下都是准确、适当和完整的, 亦不能保证这些统计信息以及据以得出这些信息的假设能够反映荷宝上海可能遇到的市场条件或未来表现。本文中的信息是基于当前的市场情况, 这很有可能因随后的市场事件或其他原因而发生变化, 本文内容可能因此未反映最新情况,荷宝上海不负责更新本文, 或对本文中不准确或遗漏之信息进行纠正。